Loading...
Loading...
Global Hunter Securities initiates coverage on Vical Inc.
VICL with a Buy rating and a target price of $9 per share as the company makes progress on its clinical programs in 2011.
GHS says, “With the announcement of partnering TransVax development in hematopoietic stem cell transplantation with Astellas, Vical made tremendous progress advancing its clinical programs in 2011. Allovectin continues to be the key value driver, which we anticipate will position the company with the leading melanoma therapy and a blockbuster opportunity in the 2013 timeframe.”
VICL closed at $4.41 per share on Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in